Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... the most elusive targets in cancer drug discovery," said James Bradner, MD, Division Of Hematologic Neoplasia, Dana-Farber Cancer Institute. "Our research shows, for the first time, how ... is building a robust pipeline of therapeutics for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases. Aileron Therapeutics was founded in ...
2009 NOV 24 ... types of Opthalmic Pathology cases, including temporal arteritis, melanoma, epithelial, hematologic and soft tissue tumors of the eye, lacrimal gland pathology, eyelid skin and mucosal ... Data Management, Information Technologies, Technology, Arteritis, Cardiology, Corneal Disease, Diagnostics, Melanoma, Pathology, Temporal Arteritis, American International Pathology ...
Subject: American International Pathology Laboratories
2009 NOV 16 ... There were minimal effects on neutrophil counts. Minimal constitutional symptoms or hematologic effects were observed with PEG-Interferon lambda given as a single agent or in ... a single agent or in combination with ribavirin in genotype 1 HCV patients with relapsed disease and in treatment-naive patients. In the single agent arm of the study with ...
2009 NOV 16 ... in peripheral T-cell lymphoma in 2010 and continuing further investigation in additional hematologic indications and solid tumors." About CTCL CTCL is a type of non-Hodgkin's lymphoma, ... at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or ...
2009 NOV 23 ... research on the cloning of human antibodies and practiced oncology with a specialty in hematologic malignancies and bone marrow transplantation. Dr. Dessain is also involved in the ... Alzheimer's disease (AD), which afflicts over 5.3 million people in the United States alone, is the most ...
2009 NOV 16 ... and misoprostol, there were no significant associations with known risk factors or with hematologic indices within sickle cell disease," wrote D. Simmsstewart and colleagues, University ...
2009 NOV 23 ... date, eight patients (62%) are alive, four (31%) still in CR. All patients experienced hematologic toxicity (WHO 3-4) with two deaths due to septic shock," wrote E. Cavalieri and ... lymphoma (HL), while few data are available on the efficacy of this regimen in advanced disease. About 50% of patients with HL relapsed after or refractory to first-line therapy ...
2009 NOV 16 ... were nausea, fatigue, lethargy, anorexia, proteinuria, and diarrhea, with infrequent hematologic toxicities. Pharmacokinetic data indicated rapid absorption, dose proportionality, and ... of drug accumulation. Although no objective tumor responses were seen, durable stable disease was observed in 16% of patients. Dasatinib was well tolerated in this population, with a ...
2009 NOV 16 ... patients with a history of: psychosis; EEG abnormalities; bipolar disorder; depression. Hematologic monitoring is advised during prolonged treatment. Patients should avoid applying ... history, including family history, and physical exam to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and ...
2009 NOV 9 ... According to a study from Athens, Greece, "The diverse hematologic manifestations of primary Sjogren (pSS) have not been systematically investigated, and ... assess the prevalence of hematologic abnormalities and their associations with various disease manifestations in pSS." "We also aimed to identify risk factors for the ...
2009 NOV 9 ... of this study was to evaluate the frequency of CKD among patients who received HCT for hematologic and nonhematologic disorders." "We performed a prospective study to ... According to a study from Iran, "Occurrence of chronic kidney disease (CKD) after hematopoietic cell transplantation (HCT) is rare with relatively few ...
2009 NOV 16 ... Harvard Medical School, Dana-Farber Cancer Institute (DFCI), is Chief of the Division of Hematologic Neoplasia, Director of the Lipper Myeloma Center and Lebow Institute for Myeloma ... group antigens and the pathophysiological mechanisms of vaso-occlusion in sickle cell disease. She is the director of the Duke Comprehensive Sickle Cell Center. Dr. ...
2009 NOV 23 ... or ZIO-101) is a novel organic arsenic being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that ... very promising, indicating a potentially new drug to help control this life-threatening disease with acceptable safety and quality of life," commented George Demetri, MD, Director of ...
